[go: up one dir, main page]

DE60122304D1 - Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe - Google Patents

Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe

Info

Publication number
DE60122304D1
DE60122304D1 DE60122304T DE60122304T DE60122304D1 DE 60122304 D1 DE60122304 D1 DE 60122304D1 DE 60122304 T DE60122304 T DE 60122304T DE 60122304 T DE60122304 T DE 60122304T DE 60122304 D1 DE60122304 D1 DE 60122304D1
Authority
DE
Germany
Prior art keywords
lipiden
active substances
based system
targeted administration
diagnostic active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60122304T
Other languages
English (en)
Other versions
DE60122304T2 (de
Inventor
Kent Jorgensen
Jesper Davidsen
Charlotte Vermehren
Sven Frokjaer
G Mouritsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liplasome Pharma ApS
Original Assignee
Liplasome Pharma ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma ApS filed Critical Liplasome Pharma ApS
Publication of DE60122304D1 publication Critical patent/DE60122304D1/de
Application granted granted Critical
Publication of DE60122304T2 publication Critical patent/DE60122304T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Cosmetics (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
DE60122304T 2000-04-12 2001-04-11 Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe Expired - Fee Related DE60122304T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200000616 2000-04-12
DKPA200000616 2000-04-12
PCT/DK2001/000269 WO2001076644A2 (en) 2000-04-12 2001-04-11 Lipid-based systems for targeting diagnostic agents

Publications (2)

Publication Number Publication Date
DE60122304D1 true DE60122304D1 (de) 2006-09-28
DE60122304T2 DE60122304T2 (de) 2007-08-09

Family

ID=8159422

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60122304T Expired - Fee Related DE60122304T2 (de) 2000-04-12 2001-04-11 Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
DE60132184T Expired - Fee Related DE60132184T2 (de) 2000-04-12 2001-04-11 Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen
DE60126072T Expired - Fee Related DE60126072T2 (de) 2000-04-12 2001-04-11 Auf lipiden basierende arzneistoffabgabesysteme zur topischen anwendung

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE60132184T Expired - Fee Related DE60132184T2 (de) 2000-04-12 2001-04-11 Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen
DE60126072T Expired - Fee Related DE60126072T2 (de) 2000-04-12 2001-04-11 Auf lipiden basierende arzneistoffabgabesysteme zur topischen anwendung

Country Status (11)

Country Link
US (4) US7368254B2 (de)
EP (3) EP1272161B1 (de)
JP (3) JP2003530362A (de)
AT (2) ATE382333T1 (de)
AU (3) AU2001248303A1 (de)
CY (2) CY1105792T1 (de)
DE (3) DE60122304T2 (de)
DK (3) DK1272160T3 (de)
ES (3) ES2270991T3 (de)
PT (3) PT1272160E (de)
WO (3) WO2001076556A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
EP1391207A1 (de) * 2001-04-24 2004-02-25 Luis Alberto Costa Verwendung einer phospholipase a2 zur herstellung von pharmazeutischen und/oder kosmetischen zusammensetzungen zur topischen und/oder systemischen behandlung und/oder prävention von krankheiten und/oder prozessen, die durch intra- und extrazelluläre erreger ausgelöst werden, die membran-phospholipide exprimieren
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2004264857B2 (en) * 2003-07-09 2010-06-10 Sutter West Bay Hospitals Remote detection of substance delivery to cells
US20050266066A1 (en) * 2003-10-20 2005-12-01 Nof Corporation Phospholipid membrane preparation
WO2005077963A1 (fr) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais DErivEs de saccharides et d'itols possEdant un groupement O-alkyle ou un groupement O-alkyle et un groupement O-n-butanoyle. Applications comme mEdicaments dans les pathologies prolifEratives tumorales ou bEnignes.
WO2005073718A1 (ja) * 2004-01-28 2005-08-11 Ltt Bio-Pharma Co., Ltd. 胃粘膜に安全な化合物のスクリーニング方法
DE102004010387A1 (de) * 2004-03-03 2005-09-22 Siemens Ag Kontrastmittel für die Röntgen-Computertomographie
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20090110633A1 (en) * 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
SI1933809T1 (sl) * 2005-10-11 2012-08-31 Yissum Res Dev Co Sestavki za mazalno dajanje
WO2007071402A1 (en) * 2005-12-23 2007-06-28 Jado Technologies Gmbh Means and methods for the treatment and prevention of allergic diseases
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
DE112010003355T5 (de) 2009-08-21 2012-07-12 Targeted Delivery Technologies Ltd. Veskuläre Formulierungen
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) * 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
US20150306035A1 (en) * 2012-03-09 2015-10-29 Universidade Federal De Minas Gerais- Ufmg Pharmaceutical composition containing conventional liposomes and prolonged-circulation liposomes for the treatment of visceral leishmaniasis
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
US20140079773A1 (en) * 2012-09-18 2014-03-20 Comfort Care For Animals Llc Encapsulating liposomes
PT3316857T (pt) 2015-06-30 2021-11-03 Sequessome Tech Holdings Limited Composições multifásicas
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
FR2638639A1 (fr) * 1988-11-08 1990-05-11 Parincos Parfumerie Cosmet Int Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US4874794A (en) * 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
JPH0370491A (ja) 1989-08-04 1991-03-26 Toshiba Corp 電動機制御装置
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
WO1992003122A1 (de) * 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5723115A (en) * 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US5827836A (en) * 1996-11-15 1998-10-27 Clarion Pharmaceuticals Inc. Retinoid glycerol phospholipid conjugates
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6444640B1 (en) * 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof

Also Published As

Publication number Publication date
DE60126072D1 (de) 2007-03-08
WO2001076555A2 (en) 2001-10-18
US20070134153A1 (en) 2007-06-14
WO2001076555A3 (en) 2002-03-14
DE60126072T2 (de) 2007-11-08
EP1272161A2 (de) 2003-01-08
JP2003530338A (ja) 2003-10-14
DE60122304T2 (de) 2007-08-09
PT1272161E (pt) 2008-02-08
US7166297B2 (en) 2007-01-23
ES2295149T3 (es) 2008-04-16
DK1272161T3 (da) 2008-05-19
AU2001248302A1 (en) 2001-10-23
DE60132184T2 (de) 2009-01-15
AU2001248301A1 (en) 2001-10-23
EP1272160A2 (de) 2003-01-08
US7368254B2 (en) 2008-05-06
WO2001076556A3 (en) 2002-07-11
DK1272160T3 (da) 2007-05-21
US20030162748A1 (en) 2003-08-28
WO2001076556A2 (en) 2001-10-18
WO2001076644A3 (en) 2002-03-14
EP1272225B1 (de) 2006-08-16
DK1272225T3 (da) 2006-12-27
JP2003530362A (ja) 2003-10-14
AU2001248303A1 (en) 2001-10-23
US20030170297A1 (en) 2003-09-11
PT1272160E (pt) 2007-04-30
ATE336267T1 (de) 2006-09-15
JP2003530339A (ja) 2003-10-14
WO2001076644A2 (en) 2001-10-18
EP1272161B1 (de) 2008-01-02
EP1272160B1 (de) 2007-01-17
CY1106462T1 (el) 2012-01-25
ES2280355T3 (es) 2007-09-16
US20030175205A1 (en) 2003-09-18
ATE382333T1 (de) 2008-01-15
EP1272225A2 (de) 2003-01-08
PT1272225E (pt) 2007-01-31
DE60132184D1 (de) 2008-02-14
ES2270991T3 (es) 2007-04-16
CY1105792T1 (el) 2011-02-02

Similar Documents

Publication Publication Date Title
DE60122304D1 (de) Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
DE60142840D1 (de) Durch phagendisplay identifizierte zielpeptide des menschen und der maus
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
EP1119362A4 (de) Verwendungsmethode von tetracyclinverbindungen zur steigerung der interleukin-10 produktion
EP0693281A3 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
EP2824175A3 (de) Mesenchymale Stammzellen und Verwendungen dafür
PL360262A1 (pl) Kompozycje polimerycznych micelli
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
EP1100522A4 (de) Verabreichung aktiver wirkstoffe über die lunge
DE69835692D1 (de) Geladene lipide und deren verwendung
TW200611695A (en) Pyrrolopyridine derivatives
GT200000035AA (es) Derivados de resorcinol, (solicitud fraccionaria no. 1 derivada de la patente pi-2000-0035)
ATE418965T1 (de) Medikamentöse gezielte lokale lipolyse
BR0013014A (pt) Derivados de 6-aza uracila inibindo interleucina-5
BR9911885A (pt) Inibidores da angiogênese
BR0009194A (pt) Composição do resorcinol
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
Russell From my perspective. Of all the changes occurring within our health care system, perhaps the ones that affect surgeons the most are the cultural shifts that seem to be shaking the very foundation of our profession
BRPI0508053A (pt) método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto
EP1583777A4 (de) Verfahren zur therapie und diagnose durch targeting von zellen, die ly-9 exprimieren
BR0212274A (pt) Uso de estrogênios não-feminilizantes como agentes retinoprotetores para o tratamento de glaucoma
DK1257538T3 (da) 9-alkylamino-1-nitroacridin-derivater
NEONATORUM boiling destroys the food-supply of the infection.
UY25164A1 (es) 3-ariluracilos herbicidas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee